Introduction
Regression analysis was used to assess the relationship between changes in platelet n-3 fatty 181 acids, eGFR and C-reactive protein (CRP) with plasma SPMs at baseline and after 182 intervention adjusting for baseline values.
Results

186
Patient Characteristics
187
The CONSORT diagram for the study has been previously published, Mori et al. 17 .
188
At baseline there were 63 men and 22 women aged 56.5±1.4 years with a BMI of 27.3±0. 
Effects of n-3 fatty acids on platelet phospholipid fatty acids
195
Baseline platelet phospholipid fatty acids were not different between the groups
196
( Table 2 ). The changes in long-chain n-3 fatty acids confirmed compliance with capsule 197 intake ( Table 2) . EPA (20:5n-3) and DHA (22:6n-3) were both increased (P<0.0001) and
198
arachidonic acid (20:4n-6) was reduced (P=0.027) in the two groups consuming n-3 fatty 199 acids relative to the groups not supplemented with n-3 fatty acids (Table 2) . (Table   211 3). Plasma levels of 10S,17S-diHDHA and protectin PD1 were below the limit of 212 quantification as assessed by Mas et al. 15 .
213
In regression analysis adjusting for baseline measures, the post-intervention 
218
There were no significant relationships between any of the SPMs and renal function 219 or CRP at baseline or after n-3 fatty acid supplementation. 
229
Plasma 18-HEPE in patients taking n-3 fatty acids was increased 4-5-fold relative to 230 the group not taking n-3 fatty acids and was significantly related to the increase in platelet
231
EPA. Plasma 17-HDHA was 1-2 fold higher in the n-3 fatty acid group and was significantly 232 related to the increase in platelet DHA after n-3 fatty acid supplementation. Patients with
233
CKD have reduced levels of plasma n-3 fatty acids compared with healthy individuals 20 , and thus a reduced capacity to synthesize SPMs under basal conditions. Therefore, the finding 235 that supplementing CKD patients with n-3 fatty acids can reverse these deficiencies is 236 clinically significant.
237
The fact that RvD1 and 17-HDHA were significantly increased with n-3 fatty acids in 238 our study is important because both of these SPMs have been shown to be biologically active.
239
In a mouse model of acute kidney injury, 17-HDHA and RvD1 are generated after ischemia regarding the effects of n-3 fatty acids on CRP in CKD patients. CRP levels were unchanged 267 in patients with stage 4-5 CKD, who were given 1.8g or 3.6g of n-3 fatty acids daily for 10 268 weeks 33 , and in hemodialysis patients that received 3g/day of n-3 fatty acids for 2 months 34 .
269
In contrast, a significant reduction in CRP was observed in hemodialysis patients after 4 270 months supplementation with n-3 fatty acids (900mg/day) 35 , and in patients with end-stage 271 renal disease who were given 1.56g/day of n-3 fatty acids for 6 months 36 . It has been 272 suggested that n-3 fatty acids are more effective when CRP is elevated at baseline and this 273 may in part have contributed to the different study outcomes 37, 38 .
274
Limitations in our study include the relatively short period of n-3 fatty acid 
281
In conclusion, n-3 fatty acid supplementation for 8 weeks increases the synthesis of
282
SPMs that are vital for the resolution of inflammation and return to homeostasis. This study 283 suggests that long term n-3 fatty acid supplementation is a potential therapy for limiting the low grade inflammation that associates with, and exacerbates, the progression of chronic 285 kidney disease. patients, interpretation of results and the revision of the manuscript.
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